CA Patent

CA3100050A1 — Systems and methods for closed loop, real-time modifications of patient cells

Assigned to Lupagen Inc · Expires 2019-11-14 · 7y expired

What this patent protects

Provided herein are bedside systems and methods for performing customized cell-based therapies and treatments in a patient-connected, closed-loop continuous-flow manner, including cellular modifications and treatments, e.g., to produce chimeric antigen receptor -T (CAR-T) cells a…

USPTO Abstract

Provided herein are bedside systems and methods for performing customized cell-based therapies and treatments in a patient-connected, closed-loop continuous-flow manner, including cellular modifications and treatments, e.g., to produce chimeric antigen receptor -T (CAR-T) cells among other cellular modifications and treatments.

Drugs covered by this patent

Patent Metadata

Patent number
CA3100050A1
Jurisdiction
CA
Classification
—
Expires
2019-11-14
Drug substance claim
No
Drug product claim
No
Assignee
Lupagen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.